Provider review
Hims & Hers tirzepatide review
What Hims & Hers charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
We re-read Hims & Hers’s own pages on November 20, 2026. Hims & Hers’ weight-loss pages could not be re-read on November 20, 2026. Its November 6, 2026 release with Lilly puts brand Zepbound from $299 a month at Lilly’s self-pay price on its platform, and its third-quarter 10-Q says compounded GLP-1s are now offered only ‘on a limited scale’. Hims & Hers is not scored in our November 20, 2026 computed ranking because it has no compounded tirzepatide price we could read on its own pages that day. Sections below that show July 2026 records are kept as dated history.
What is distinctive about this programme
The membership is the story
At $149 a month, the Hims and Hers membership equals or exceeds the medication price on their lowest-cost brand option. Oral Wegovy tablets at $149 medication become $298 all-in — double.
For comparison, the identical oral Wegovy tablets are $149 direct from NovoCare with no membership at all. A patient buying through the platform is paying $1,788 a year for the service layer.
The $39 first-month membership is introductory and rises to $149.
Where it is competitive, and where it is not
At $348 all-in for the Wegovy pen and $448 for Zepbound, Hims and Hers sit above PlushCare's $319 for Zepbound and well above manufacturer-direct pricing. Our dataset also flags one listing — a Hers KwikPen price — as unconfirmed, because Lilly's vial-only self-pay programme does not include the pre-filled KwikPen. Verify at checkout.
Hers also lists brand Mounjaro at $1,899 medication plus $149 membership, or $2,048 all-in — the highest single figure in our entire dataset. No manufacturer self-pay programme exists for Mounjaro, but Zepbound is the identical molecule at $299 to $449 direct.
What the membership buys
Ongoing clinical access, messaging and a consumer platform many patients already use for other categories. Whether that is worth $1,788 a year alongside medication is a judgement, but it should be made with the manufacturer-direct price in view.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide brand oral, FDA-approved | $298 | Reported |
| Tirzepatide brand injectable, FDA-approved | $2,048 | Reported |
Where it holds up
- Established platform with broad clinical access and messaging
- Same price at all doses on some brand products
- Wide range of brand options in one place
Where it does not
- $149 monthly membership doubles the cost of the cheapest brand option
- Oral Wegovy at $298 all-in against $149 direct from NovoCare
- One KwikPen listing is unconfirmed against Lilly's vial-only self-pay programme
- Brand Mounjaro at $2,048 all-in is the highest figure in our dataset
- First-month membership rate is introductory
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $298/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
Show this figure as a table
| Category | Points |
|---|---|
| Pricing transparency | 20 pts |
| Total annual cost | 20 pts |
| Clinical oversight | 15 pts |
| Pharmacy transparency | 15 pts |
| Support | 10 pts |
| Regulatory disclosure | 10 pts |
| Accessibility | 10 pts |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Hims | month_to_month | brand oral, FDA-approved | — | $298 | — | $298 | Recurring | Reported | 2026-07-06 |
| Hers | month_to_month | brand injectable, FDA-approved | — | $2,048 | — | $2,048 | Recurring | Reported | 2026-07-06 |
How this sits against the market
Show this figure as a table
| Program | All-in monthly | Read |
|---|---|---|
| Collective | $85.58 | Read 2026-10-15 |
| WellMedr | $89 | Read 2026-10-15 |
| Mondae | $114 | Read 2026-10-15 |
| NexLife | $115 | Read 2026-11-06 |
| Embody | $119 | Read 2026-10-15 |
| NextMeds | $119 | Read 2026-10-15 |
| SnagRx | $119 | Read 2026-10-15 |
| yourEra | $123 | Read 2026-10-15 |
| NewMeMeds | $125 | Older record, 2026-09-20 |
| CoreAge Rx | $129 | Read 2026-10-15 |
| Eden Health | $129 | Read 2026-10-15 |
| SkinnyRx | $129 | Older record, 2026-08-27 |
| GobyMeds | $133 | Read 2026-10-15 |
| Telos RX | $139 | Read 2026-10-15 |
| Sprout Health | $149 | Read 2026-10-15 |
| Strut Health | $149 | Read 2026-10-15 |
| He & She MD | $159 | Read 2026-10-15 |
| Bodybuilding Health+ | $174.67 | Read 2026-10-15 |
| bmiMD | $179 | Older record, 2026-09-17 |
| IVIM Health | $192 | Read 2026-10-15 |
| Alloy | $199 | Read 2026-10-15 |
| TelePep | $214 | Read 2026-10-15 |
| Yucca Health | $225 | Older record, 2026-09-12 |
| Found | $239 | Read 2026-10-15 |
| Pallas Health | $239 | Read 2026-10-15 |
| ShedRx | $239 | Read 2026-10-15 |
| MyDrHank | $240 | Older record, 2026-09-17 |
| Enhance.MD | $280 | Read 2026-10-15 |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | — |
| Shipping | no | — |
| Higher-dose surcharge | no | — |
| Initial consultation | no | — |
| Required laboratory work | no | — |
| Cancellation or restocking terms | no | — |
A dash means no figure held. How we grade evidence.
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Clinical model
Pharmacy and fulfilment
Billing, cancellation and support
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Hims & Hers sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered Pending |
| Clinical oversight and care continuity | 20 pts | — | Not answered Pending |
| State access and operational reliability | 10 pts | — | Not answered Pending |
| Cancellation, billing and support transparency | 10 pts | — | Not answered Pending |
A dash means no figure held. How we grade evidence.
Questions readers actually ask
Is Hims & Hers the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. Reviews here are not sponsored, and no provider can buy a score, a placement or a review. Tirzepatide Ranked is affiliate-supported; the disclosure page explains how.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Mochi Health Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Mounjaro vs ZepboundPillar / Money
- Zepbound vs MounjaroComparisons
- Tirzepatide Cost in 2026Pillar / Money
Related coverage
Tirzepatide Ranked. “Hims & Hers Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/hims-hers/
Quote the capture date beside a figure, not the date you read this page. Why.
How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.